<?xml version="1.0" encoding="utf-8"?>
<Document>
  <Do_id>17356951</Do_id>
  <Journal>Annals of surgical oncology</Journal>
  <Doc_title>Should surgical resection be combined with imatinib therapy for locally advanced or metastatic gastrointestinal stromal tumors?</Doc_title>
  <Doc_abstract>None</Doc_abstract>
  <Doc_ChemicalList>Antineoplastic Agents;Benzamides;Piperazines;Protein Kinase Inhibitors;Pyrimidines;Imatinib Mesylate;Protein-Tyrosine Kinases</Doc_ChemicalList>
  <Doc_meshdescriptors>Antineoplastic Agents;Benzamides;Drug Administration Schedule;Elective Surgical Procedures;Follow-Up Studies;Gastrointestinal Stromal Tumors;Humans;Imatinib Mesylate;Neoadjuvant Therapy;Piperazines;Protein Kinase Inhibitors;Protein-Tyrosine Kinases;Pyrimidines;Retrospective Studies;Survival Rate;Time Factors;Treatment Outcome</Doc_meshdescriptors>
  <Doc_meshqualifiers>administration &amp; dosage;therapeutic use;drug therapy;secondary;surgery;administration &amp; dosage;therapeutic use;administration &amp; dosage;therapeutic use;antagonists &amp; inhibitors;administration &amp; dosage;therapeutic use</Doc_meshqualifiers>
</Document>
